Stryker (NYSE:SYK) Price Target Cut to $350.00 by Analysts at JPMorgan Chase & Co.

Stryker (NYSE:SYK) had its price target cut by JPMorgan Chase & Co. from $400.00 to $350.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 7.63% from the stock’s current price.

A number of other analysts also recently weighed in on SYK. Wells Fargo & Company decreased their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Barclays dropped their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Canaccord Genuity Group decreased their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, BTIG Research cut their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $387.88.

Stryker Trading Down 6.6%

NYSE:SYK traded down $22.85 during trading hours on Friday, hitting $325.19. 2,843,080 shares of the company were exchanged, compared to its average volume of 2,367,306. The stock has a market capitalization of $124.67 billion, a price-to-earnings ratio of 37.64, a price-to-earnings-growth ratio of 2.26 and a beta of 0.77. Stryker has a one year low of $281.00 and a one year high of $401.99. The company has a fifty day simple moving average of $317.08 and a 200 day simple moving average of $334.98. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker will post 14.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the transaction, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp increased its position in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after acquiring an additional 311,507 shares in the last quarter. Geode Capital Management LLC boosted its stake in Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after purchasing an additional 1,198,665 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Stryker in the fourth quarter valued at approximately $1,822,272,000. Institutional investors own 77.09% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter adjusted EPS of $3.69, above the $3.49 analyst consensus, while revenue rose 9.4% year over year to $6.59 billion, broadly matching expectations. Strong demand for orthopedic, spinal and other medical devices supported the results. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Organic sales growth reached approximately 9%, and management said operations are recovering from the cyber disruption. Stryker also plans to resume share repurchases, which could provide support for the stock. Stryker expects organic sales growth and adjusted EPS in 2026
• Positive Sentiment: Analysts remain generally constructive: BTIG maintained a “buy” rating with a $358 price target, while Truist raised its target to $340, although Truist kept a “hold” rating. BTIG Research updates Stryker price target
• Neutral Sentiment: Stryker forecast 2026 adjusted EPS of $14.95-$15.10 and organic sales growth of 8.3%-9.3%. The range remains close to consensus, but its narrower outlook gives investors less room for upside surprises. Stryker posts Q2 beats and narrows guidance
• Negative Sentiment: The stock’s decline reflects disappointment that the earnings beat did not translate into a stronger outlook. Investors remain concerned about the lingering financial and operational effects of the cyberattack, including the pace of the recovery and potential execution risks. SYK falls despite Q2 earnings beat

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.